Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B

[Guest guest]

http://www.wjgnet.com/1007-9327/abstract_en.asp?f=4713 & v=14

World J Gastroenterol 2008 August;14(29):4713-4715

Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b

therapy in a patient with chronic hepatitis B

Lv YY, Shi BY, Guo H.

Department of Endocrinology, First Affiliated Hospital, Medical School of Xi'an

Jiaotong University, 277 Yanta West Road, Xi'an 710061, Shaanxi Province, China.

shibingy@...

We describe a case of a 33-year-old female patient with chronic hepatitis B who

developed type 1 diabetes mellitus (DM) after a 13-mo period of treatment with

recombinant human interferon-alpha (IFN-alpha) 2b. The patient presented with

polydipsia, polyuria, hyperglycemia, diabetic ketoacidosis, combined with

C-peptide secretion deficiency and positive islet cell autoantibody (ICAb).

IFN-alpha 2b treatment was terminated and instead insulin treatment was

initiated. Five months after cessation of the recombinant human IFN-alpha 2b

therapy, the patient remained insulin-dependent. Her serum HBV DNA became

negative and serum transaminase returned to the normal level after a 10-mo

period of IFN therapy. Type 1 DM induced by IFN-alpha is relatively rare in

patients with chronic hepatitis B. We should pay more attention to patients on

IFN-alpha therapy to avoid destruction of pancreatic beta cells. This is the

first case report from China.

[Guest guest]

http://www.wjgnet.com/1007-9327/abstract_en.asp?f=4713 & v=14

World J Gastroenterol 2008 August;14(29):4713-4715

Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b

therapy in a patient with chronic hepatitis B

Lv YY, Shi BY, Guo H.

Department of Endocrinology, First Affiliated Hospital, Medical School of Xi'an

Jiaotong University, 277 Yanta West Road, Xi'an 710061, Shaanxi Province, China.

shibingy@...

We describe a case of a 33-year-old female patient with chronic hepatitis B who

developed type 1 diabetes mellitus (DM) after a 13-mo period of treatment with

recombinant human interferon-alpha (IFN-alpha) 2b. The patient presented with

polydipsia, polyuria, hyperglycemia, diabetic ketoacidosis, combined with

C-peptide secretion deficiency and positive islet cell autoantibody (ICAb).

IFN-alpha 2b treatment was terminated and instead insulin treatment was

initiated. Five months after cessation of the recombinant human IFN-alpha 2b

therapy, the patient remained insulin-dependent. Her serum HBV DNA became

negative and serum transaminase returned to the normal level after a 10-mo

period of IFN therapy. Type 1 DM induced by IFN-alpha is relatively rare in

patients with chronic hepatitis B. We should pay more attention to patients on

IFN-alpha therapy to avoid destruction of pancreatic beta cells. This is the

first case report from China.